Getting Ozempic is straightforward if you have a type 2 diabetes diagnosis and insurance that covers it, but significantly harder if you’re trying to get it for weight loss. The drug is FDA-approved only for type 2 diabetes, not weight management, which means the path to a prescription depends almost entirely on why you want it and how you plan to pay.
What Ozempic Is Actually Approved For
Ozempic is approved for three specific uses in adults with type 2 diabetes: improving blood sugar control alongside diet and exercise, reducing the risk of heart attack, stroke, and cardiovascular death in people with established heart disease, and protecting kidney function in people with chronic kidney disease. That’s it. There is no FDA approval for Ozempic as a weight loss drug.
The weight loss version of semaglutide (the same active ingredient) is sold under a different brand name, Wegovy, at higher doses and with its own approval for chronic weight management. Many people searching for Ozempic are actually looking for the weight loss benefit, and that distinction shapes every step of whether you can get it, whether insurance will pay, and how much it costs.
The Insurance Hurdle
Most insurance plans require prior authorization before they’ll cover Ozempic, and the criteria are specific. Aetna’s policy is a representative example: you need a type 2 diabetes diagnosis, and if you haven’t already been on a similar medication for at least three months, you generally need to show that a first-line diabetes drug like metformin didn’t work, caused side effects, or isn’t safe for you. Alternatively, your blood sugar levels (measured by A1C) need to be 7.5% or higher while on combination therapy, or you need to have established cardiovascular disease.
If you’ve already been on a similar medication for three months or more, insurers typically want to see that your A1C has actually dropped since starting it. This means your doctor can’t just write a prescription and send you to the pharmacy. They’ll need to submit clinical documentation, and approval can take days to weeks. Some plans deny the first request, requiring an appeal.
For people seeking Ozempic specifically for weight loss, most insurance plans won’t cover it at all under that indication. Some plans cover Wegovy for weight management, but many exclude weight loss medications entirely. Employer-sponsored plans vary widely, and Medicare Part D generally does not cover drugs prescribed for weight loss.
What It Costs Without Insurance
The list price for a single Ozempic pen is $1,027.51. In practice, the retail cost without insurance runs about $349 per month for the 0.25 mg, 0.5 mg, or 1 mg doses, and $499 per month for the 2 mg dose. New patients paying out of pocket can get the first two months (the lower starter doses) for $199 per month through manufacturer pricing programs.
These prices put Ozempic out of reach for many people without coverage. At $349 to $499 a month, you’re looking at roughly $4,200 to $6,000 a year as an ongoing expense, since stopping the medication typically means the benefits stop too.
Telehealth and Online Prescribers
A growing number of telehealth companies advertise easy access to semaglutide prescriptions, often with a quick online consultation and no in-person visit. Some of these services prescribe brand-name Ozempic or Wegovy, while others have historically offered compounded versions of semaglutide at lower prices. The experience can feel remarkably easy: fill out a questionnaire, have a brief video call, and receive a prescription or a shipment.
The catch is that a legitimate prescriber still needs a valid medical reason to write the prescription. If you don’t have type 2 diabetes, an honest provider should be prescribing Wegovy (not Ozempic) for weight management, and only if you meet the BMI criteria for that drug. Some telehealth platforms are more rigorous about this than others, and the quality of medical oversight varies significantly.
Compounded Semaglutide Is Getting Harder to Find
During the semaglutide shortage, compounding pharmacies were allowed to produce their own versions of the drug, which medspas, clinics, and telehealth companies sold at a fraction of brand-name prices. That window has largely closed. The FDA declared the semaglutide injection shortage resolved in February 2025, which triggers restrictions on compounding.
Under current FDA rules, compounded drugs are not FDA-approved and don’t go through the same safety and effectiveness review. Now that the shortage is resolved, state-licensed pharmacies compounding semaglutide under standard compounding rules (called section 503A) have lost their enforcement discretion. Larger outsourcing facilities had a grace period that extended to May 2025, but semaglutide does not appear on the FDA’s approved bulk drug substance list, meaning there’s no long-term legal pathway for most compounders to keep making it.
In practical terms, compounded semaglutide is becoming much harder to obtain legally. Some compounding pharmacies are still operating in a legal gray area, but ordering from them carries risk: you may receive a product with inconsistent dosing, questionable sterility, or no real semaglutide at all.
Counterfeit Ozempic Is a Real Risk
The FDA has issued multiple warnings about counterfeit Ozempic pens found in the U.S. drug supply chain. At least three specific lot numbers (PAR1229, PAR0362, and NAR0074) have been identified as counterfeits. In one case, analysis found that even the needles packaged with the pens were counterfeit, meaning their sterility couldn’t be confirmed.
You can spot some counterfeits by examining the pen label. On authentic Ozempic pens, the text reading “EXP/LOT” appears above the expiration date and lot number. On at least one batch of counterfeits, that text appeared to the left instead. If you’re buying Ozempic from any source other than a licensed U.S. pharmacy, including online sellers, international pharmacies, or social media contacts, the risk of receiving a counterfeit product goes up substantially.
The Realistic Picture
If you have type 2 diabetes and insurance, getting Ozempic is a moderate hassle. You’ll need your doctor to submit prior authorization paperwork, possibly try metformin first, and wait for approval. Once approved, your copay depends on your plan, but manufacturer savings cards can bring it down for commercially insured patients.
If you want semaglutide for weight loss, the honest path is asking your doctor about Wegovy, not Ozempic, and being prepared to pay out of pocket if your insurance excludes weight loss drugs. Some people do get Ozempic prescribed off-label for weight loss, but insurance almost never covers it for that purpose, and you’ll pay full retail price.
If you’re uninsured and looking for the lowest-cost option, the landscape has shifted. Cheap compounded semaglutide was widely available in 2023 and 2024, but regulatory changes have closed most of those doors. What remains are brand-name prices in the $350 to $500 per month range, with limited introductory discounts for new patients.